State of New Jersey Common Pension Fund D Buys 10,937 Shares of Haemonetics Corporation $HAE

State of New Jersey Common Pension Fund D increased its stake in Haemonetics Corporation (NYSE:HAE) by 38.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,405 shares of the medical instruments supplier’s stock after buying an additional 10,937 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Haemonetics were worth $1,921,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Haemonetics in the 2nd quarter worth approximately $36,822,000. SG Capital Management LLC raised its holdings in Haemonetics by 92.5% in the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares in the last quarter. AQR Capital Management LLC lifted its position in Haemonetics by 157.9% during the second quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier’s stock valued at $33,390,000 after buying an additional 275,683 shares during the period. River Road Asset Management LLC boosted its holdings in shares of Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after buying an additional 260,624 shares in the last quarter. Finally, ABN Amro Investment Solutions purchased a new stake in shares of Haemonetics in the 3rd quarter worth about $186,000. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $62.37 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The firm’s 50-day moving average price is $70.83 and its 200-day moving average price is $63.97. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32. The company has a market cap of $2.90 billion, a PE ratio of 17.18, a PEG ratio of 1.29 and a beta of 0.28.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the topic of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.